Jerome Hauer - EMERGENT BIOSOLUT Independent Director
| ER4 Stock | EUR 9.49 0.01 0.11% |
Director
Dr. Jerome M. Hauer, Ph.D., is an Independent Director of the Company. He previously served on our Board of Directors from May 2004 to October 2011. Currently, Dr. Hauer is a senior advisor at Teneo Risk in New York City and Washington, D.C. and a visiting professor at Cranfield UniversityDefence Academy of the United Kingdom. Before joining Teneo Risk, Dr. Hauer served from January 2012 until December 2014 as the Commissioner of New York State Division of Homeland Security and Emergency Services and Chairman of the Executive Committee on Counterterrorism. Formerly, Dr. Hauer served as chief executive officer of The Hauer Group from 2006 to 2011 and as senior vice president and cochair of the homeland security practice of FleishmanHillard Government Relations from January 2005 to March 2006. Prior to joining FleishmanHillard, Dr. Hauer served as acting assistant secretary for the office of public health emergency preparedness at HHS from June 2002 to November 2003 and as director of the office of public health preparedness of HHS from May 2002 to June 2002. Dr. Hauer served as the first director of the New York City Mayor Office of Emergency Management under Mayor Rudolph Giuliani. He also served as the director of Emergency Medical Services and Emergency Management as well as director of the Department of Fire and Buildings for the State of Indiana under Governor Evan Bayh since 2015.
| Age | 67 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
Similar Executives
| Found 7 records | DIRECTOR Age | ||
| Harriett Taggart | The Hanover Insurance | 71 | |
| Jane Carlin | The Hanover Insurance | 63 | |
| Daniel Henry | The Hanover Insurance | 69 | |
| Joseph Ramrath | The Hanover Insurance | 62 | |
| Kathleen Lane | The Hanover Insurance | 61 | |
| Wendell Knox | The Hanover Insurance | 71 | |
| Kevin Bradicich | The Hanover Insurance | 61 | |
EMERGENT BIOSOLUT Leadership Team
Elected by the shareholders, the EMERGENT BIOSOLUT's board of directors comprises two types of representatives: EMERGENT BIOSOLUT inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EMERGENT. The board's role is to monitor EMERGENT BIOSOLUT's management team and ensure that shareholders' interests are well served. EMERGENT BIOSOLUT's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EMERGENT BIOSOLUT's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Sean Kirk, Executive Vice President Manufacturing and Technical Operations | ||
| Katherine Strei, Executive Vice President, Human Resources and Communications, Chief Human Resources Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Marvin White, Director | ||
| Kathryn Zoon, Independent Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Adam Havey, Executive Vice President and Presidentident - BioDefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Independent Director | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
EMERGENT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is EMERGENT BIOSOLUT a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.34 B | |||
| Price To Book | 0.43 X | |||
| Price To Sales | 0.42 X | |||
| Revenue | 1.12 B | |||
| EBITDA | (41.1 M) | |||
| Net Income | (223.8 M) | |||
| Total Debt | 448.5 M | |||
| Cash Flow From Operations | (34.1 M) | |||
| Number Of Employees | 18 | |||
| Market Capitalization | 1.91 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in EMERGENT Stock
EMERGENT BIOSOLUT financial ratios help investors to determine whether EMERGENT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in EMERGENT with respect to the benefits of owning EMERGENT BIOSOLUT security.